News | 17 September 2024
Panacea Biotec and Sanofi reached settlement agreement for Shan6
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Total investment incurred for setting up the new R&D Rs 250 crore
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Lasa Supergenerics Limited has been granted patent for an invention “Processes for Preparation and Purification of 5-Chloro-2-Nitroaniline
The acquisition is based on an enterprise value of Rs. 1,660 crore
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The company will now seek final approval from NCLT, Mumbai Bench, and upon its receipt, OneSource will proceed to seek listing approvals from the BSE and NSE
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies
This case is an isolated case, similar to the earlier 30 cases reported in India from July 2022 onwards
Wanbury receives CEP approval from EDQM for launch of Dextromethorphan API
Agreement further expands Aptar Pharma’s leading respiratory portfolio
The collaborations will help curate industry focused courses such as Advanced Certification courses for healthcare professionals in Healthcare Marketing, Healthcare Technology and Specialized Clinical Fellowship Level programs with university accreditation
Subscribe To Our Newsletter & Stay Updated
